

## First rabbit based client project started

**June 15 2016** - MEMO has started a first client project based on its *rb*MemoMAB™ antibody discovery technology.

### About Memo Therapeutics AG

Memo Therapeutics is an innovator in the area of recombinant immunoglobulins and human-derived monoclonal antibodies. The technological core of Memo Therapeutics is MemoMAB™ – a technology enabling cost and time-effective molecular cloning and expression of the complete antibody repertoire of one or several human subjects.

Memo Therapeutics capitalizes on the MemoMAB™ platform by developing proprietary technologies and products and by offering services in the area of recombinant immunoglobulins and monoclonal antibodies.